USANA Health Sciences Inc. - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended April 4, 2026. USANA Health Sciences, Inc. operates as a global nutritional and wellness company organized into three reportable segments: Core Nutritional (direct sales), Hiya (direct-to-consumer children's health), and Rise (retail protein products). Effective January 4, 2026, the company reorganized its segments to reflect how management evaluates performance, recasting prior period data accordingly.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Sales | $250.2 million | $249.5 million |
| Gross Profit | $190.8 million (76.2% margin) | $197.1 million (79.0% margin) |
| Operating Income | $13.9 million | $15.7 million |
| Net Earnings (USANA) | $7.5 million | $9.4 million |
| Diluted EPS | $0.41 | $0.49 |
| Cash from Operations | $9.8 million | $15.5 million |
| Cash & Equivalents | $162.8 million | $179.6 million |
| Debt (Line of Credit) | $14.0 million | $14.0 million |
Material Changes vs. Prior Period
- Revenue Mix Shift: Consolidated net sales increased slightly (0.3%) driven by a 740.7% surge in the Rise segment ($13.7M vs $1.6M), offset by declines in Core Nutritional (-3.0%) and Hiya (-13.3%).
- Margin Compression: Consolidated gross margin decreased 280 basis points to 76.2%. This was primarily due to the lower-margin Rise segment contributing more to the mix and production inefficiencies in Core Nutritional.
- Profitability Decline: Net earnings attributable to USANA fell 20.1% to $7.5 million. This was driven by lower operating income and a significantly higher effective tax rate (55.0% vs 44.5% in the prior year).
- Customer Base Contraction: Active customers in the Core Nutritional segment dropped 12.0% year-over-year to 404,000. Hiya active monthly subscribers declined to 186,000 from 224,000.
- Cash Flow: Operating cash flow decreased to $9.8 million, impacted by higher trade receivables (due to Rise retail sales) and payments for bonuses and incentives.
Outlook, Risks, and Management Commentary
- Segment Performance: Management attributes the Core Nutritional decline to a challenging economic environment and difficulty attracting new customers, partially offset by higher average spend per customer. Rise's growth is attributed to the launch of "Protein Pop" in national retailers.
- Tax Rate: The elevated effective tax rate is due to lower consolidated earnings projections and an unfavorable mix of taxable income by market.
- Liquidity: The company maintains $162.8 million in cash and a $75 million credit facility with $14 million outstanding. Management believes current liquidity is adequate for operations.
- Key Risks:
- Dependence on the Core Nutritional direct sales model, which has seen declining sales and active customers.
- Regulatory risks in China (BabyCare subsidiary) regarding direct selling and data privacy.
- Geopolitical tensions and foreign currency volatility.
- Supply chain disruptions and raw material price increases.
- Share Repurchases: No shares were repurchased in Q1 2026. Approximately $34.0 million remains authorized under the repurchase plan.
Investor Verification Checklist
- Core Nutritional Trajectory: Verify if the 12% decline in active customers is a temporary trend or a structural shift in the direct sales model.
- Rise Margin Sustainability: Assess whether the low gross margins (7.1%) of the Rise segment will continue to drag down consolidated profitability as its sales volume grows.
- Tax Rate Volatility: Monitor future effective tax rates, as the 55% rate in Q1 significantly impacted net earnings.
- China Exposure: Review regulatory updates in China, as Greater China represents a significant portion of Core Nutritional sales ($123.3M in Q1).
- Hiya Subscriber Churn: Investigate the reasons behind the 17% drop in Hiya's active monthly subscribers and the impact of retail expansion on subscription retention.